EC Number |
Protein Variants |
Reference |
---|
3.4.22.B50 | C270A/H332A |
active site mutant |
732827 |
3.4.22.B50 | C1732A |
encodes a substitution of a cysteine residue, predicted to be critical for zinc binding |
-, 670084 |
3.4.22.B50 | C106A |
inactive |
718275 |
3.4.22.B50 | T312A/I313V/I353R |
mutant lacks deubiquitinase activity, amino acid numbering based on polyprotein |
-, 755638 |
3.4.22.B50 | T39W |
mutation enhances hydrolysis of the SARS-CoV-derived peptidyl substrate Dabcyl-FRLKGGAPIKGV-Edans |
752517 |
3.4.22.B50 | C1651A |
Plpro active-site mutant |
-, 670085 |
3.4.22.B50 | C1651A |
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues |
-, 670084 |
3.4.22.B50 | D1826A |
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues |
-, 670084 |
3.4.22.B50 | C112S |
site-directed mutagenesis, active site cysteine mutant, forms a noncovalent complex with ubiquitin, crystal structure analysis |
731149 |
3.4.22.B50 | Y274A |
site-directed mutagenesis, inactive mutant |
731069 |